Ivermectin cures cancer
Ivermectin kills cancer cells in dishes and shows some activity in animals, but no controlled human trial shows it cures or shrinks cancer. The widely shared '84.4% clinical benefit' cohort has no control group and the journal has issued an Expression of Concern about it.
AI review of the sources below, no human approval · Reviewed
This verdict was generated by AI from the papers listed on this page and published without human sign-off. AI can misread or miss studies — check the sources yourself. Not medical advice.
What the research says
The study circulating online is Hulscher et al., a prospective observational cohort of ivermectin plus mebendazole published in Anticancer Research in 2026. It is not a randomised trial: there is no comparison group, outcomes were patient-reported, and patients were also receiving conventional treatment — so an 84.4% 'clinical benefit ratio' cannot be attributed to the drugs. The same journal issued a formal Expression of Concern about that article in 2026. Beyond it, the literature is reviews of preclinical work: a 2025 review in Current Oncology Reports describes a critical translational gap and states there are no large randomised trials confirming therapeutic benefit in cancer, and a 2025 review in Pharmaceuticals notes clinical validation remains limited despite plausible laboratory mechanisms. An earlier preclinical breast-cancer study found ivermectin alone had no efficacy in vivo and only worked combined with checkpoint immunotherapy. Harm is documented: a 2025 case report describes a death from ivermectin poisoning linked to unproven anticancer use.
Caveats
- Preclinical anticancer activity is real and repurposing research is ongoing — 'not proven' is not the same as 'impossible'.
- Ivermectin is a safe, effective antiparasitic at approved doses; the problem is the cancer indication and the high self-dosed regimens.
- Absence of a randomised trial is itself the finding; if one is published, this verdict will be re-reviewed.
Evidence
- Observational studyAnticancer Research·2026
Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
The source of the viral '84.4%' figure: an uncontrolled cohort with patient-reported outcomes and concurrent conventional treatment.
Read the source - Narrative reviewAnticancer Research·2026
Expression of Concern regarding Hulscher et al., Anticancer Research 46(6):3243-3255
The journal's editorial board issued a formal Expression of Concern about that cohort study.
Read the source - Narrative reviewCurrent Oncology Reports·2025
Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?
Describes a critical translational gap and states no large-scale randomised trials confirm therapeutic benefit in cancer.
Read the source - Narrative reviewPharmaceuticals·2025
Ivermectin as an alternative anticancer agent: a review of its chemical properties and therapeutic potential
Preclinical mechanisms are encouraging, but clinical validation remains limited.
Read the source - Cohort studynpj Breast Cancer·2021
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade in breast cancer
In mice, ivermectin alone showed no efficacy in vivo; effect appeared only combined with anti-PD1.
Read the source - Narrative reviewJournal of International Medical Research·2025
Death caused by transdermal ivermectin poisoning: a case report and literature review
Documents a fatal poisoning linked to overuse driven by unproven anticancer claims.
Read the source
This page summarises published research for general information. It is not medical advice — talk to a clinician about your own situation.